Susquehanna International Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Susquehanna International Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.71M	Sell	179,500 -276,900	-61%	-$2.15M	﹤0.01%	6547
2025 Q4	$3.56M	Buy	456,400 +427,200	+1,463%	+$3.09M	﹤0.01%	4585
2025 Q3	$222K	Sell	29,200 -24,400	-46%	-$203K	﹤0.01%	10770
2025 Q2	$480K	Sell	53,600 -41,600	-44%	-$387K	﹤0.01%	9264
2025 Q1	$714K	Sell	95,200 -31,000	-25%	-$250K	﹤0.01%	8096
2024 Q4	$949K	Sell	126,200 -39,700	-24%	-$301K	﹤0.01%	7096
2024 Q3	$1.26M	Buy	165,900 +65,200	+65%	+$496K	﹤0.01%	6288
2024 Q2	$622K	Sell	100,700 -260,700	-72%	-$1.44M	﹤0.01%	7737
2024 Q1	$1.84M	Sell	361,400 -354,000	-49%	-$1.99M	﹤0.01%	5538
2023 Q4	$4.29M	Sell	715,400 -92,500	-11%	-$536K	﹤0.01%	3974
2023 Q3	$5.72M	Buy	807,900 +198,300	+33%	+$1.42M	﹤0.01%	3308
2023 Q2	$4.29M	Sell	609,600 -296,900	-33%	-$2.38M	﹤0.01%	3766
2023 Q1	$7.56M	Sell	906,500 -461,800	-34%	-$4.45M	﹤0.01%	2855
2022 Q4	$15.7M	Buy	1,368,300 +448,500	+49%	+$5.59M	﹤0.01%	1760
2022 Q3	$11.6M	Sell	919,800 -314,200	-25%	-$4.04M	﹤0.01%	1977
2022 Q2	$13.1M	Sell	1,234,000 -881,300	-42%	-$9.09M	﹤0.01%	1868
2022 Q1	$34.4M	Sell	2,115,300 -15,900	-0.7%	-$255K	0.01%	1244
2021 Q4	$29.5M	Buy	2,131,200 +223,900	+12%	+$2.96M	﹤0.01%	1485
2021 Q3	$27.4M	Buy	1,907,300 +353,600	+23%	+$5.58M	﹤0.01%	1671
2021 Q2	$24.6M	Buy	1,553,700 +437,400	+39%	+$5.94M	﹤0.01%	1806
2021 Q1	$11.4M	Buy	1,116,300 +858,600	+333%	+$8.85M	﹤0.01%	2585
2020 Q4	$1.92M	Sell	257,700 -38,000	-13%	-$196K	﹤0.01%	5186
2020 Q3	$1.02M	Sell	295,700 -231,600	-44%	-$993K	﹤0.01%	6076
2020 Q2	$2.51M	Buy	527,300 +388,400	+280%	+$1.55M	﹤0.01%	4094
2020 Q1	$278K	Buy	138,900 +120,300	+647%	+$331K	﹤0.01%	8121
2019 Q4	$64K	Sell	18,600 -34,500	-65%	-$86.8K	﹤0.01%	9282
2019 Q3	$152K	Sell	53,100 -50,600	-49%	-$157K	﹤0.01%	9311
2019 Q2	$393K	Sell	103,700 -176,300	-63%	-$1.06M	﹤0.01%	7768
2019 Q1	$2.28M	Buy	280,000 +200,700	+253%	+$1.72M	﹤0.01%	3554
2018 Q4	$640K	Buy	79,300 +16,400	+26%	+$128K	﹤0.01%	5548
2018 Q3	$480K	Sell	62,900 -77,000	-55%	-$517K	﹤0.01%	6605
2018 Q2	$802K	Sell	139,900 -17,800	-11%	-$98K	﹤0.01%	5815
2018 Q1	$752K	Buy	157,700 +60,200	+62%	+$309K	﹤0.01%	5806
2017 Q4	$479K	Buy	97,500 +32,400	+50%	+$157K	﹤0.01%	6722
2017 Q3	$341K	Sell	65,100 -25,100	-28%	-$129K	﹤0.01%	7177
2017 Q2	$502K	Sell	90,200 -223,600	-71%	-$1.36M	﹤0.01%	6634
2017 Q1	$2.64M	Sell	313,800 -357,000	-53%	-$2.48M	﹤0.01%	3244
2016 Q4	$4.25M	Buy	670,800 +499,800	+292%	+$2.6M	﹤0.01%	2683
2016 Q3	$754K	Buy	171,000 +107,800	+171%	+$431K	﹤0.01%	5329
2016 Q2	$179K	Buy	63,200 +41,100	+186%	+$128K	﹤0.01%	7689
2016 Q1	$63K	Sell	22,100 -336,000	-94%	-$1.49M	﹤0.01%	8603
2015 Q4	$3.7M	Sell	358,100 -17,100	-5%	-$170K	﹤0.01%	2956
2015 Q3	$4.28M	Buy	375,200 +90,700	+32%	+$1.21M	﹤0.01%	2906
2015 Q2	$4.25M	Buy	284,500 +7,200	+3%	+$81.9K	﹤0.01%	3180
2015 Q1	$2.5M	Buy	277,300 +25,600	+10%	+$265K	﹤0.01%	3876
2014 Q4	$3.06M	Sell	251,700 -21,600	-8%	-$239K	﹤0.01%	3711
2014 Q3	$2.67M	Sell	273,300 -82,600	-23%	-$1.01M	﹤0.01%	4100
2014 Q2	$4.54M	Sell	355,900 -481,500	-57%	-$4.68M	﹤0.01%	3252
2014 Q1	$8.86M	Buy	837,400 +190,900	+30%	+$2.04M	﹤0.01%	2151
2013 Q4	$4.91M	Buy	646,500 +284,600	+79%	+$1.8M	﹤0.01%	2968
2013 Q3	$2.63M	Buy	361,900 +342,900	+1,805%	+$1.74M	﹤0.01%	3676
2013 Q2	$29K	Buy	+19,000	New	+$32.8K	﹤0.01%	8058

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Susquehanna International Group's BCRX Position: Q1 2026 in Review

Susquehanna International Group increased its BioCryst Pharmaceuticals (BCRX) stake by 319% in Q1 2026, buying an estimated $16.6M and bringing the position to 2,815,304 shares worth $26.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Susquehanna International Group first reported a position in BCRX in Q2 2013 and has held it in 42 quarters since. The position peaked at $27.6M in Q4 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Susquehanna International Group held 2,815,304 shares of BioCryst Pharmaceuticals worth $26.8M as of Q1 2026.
Susquehanna International Group bought 2,143,611 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $16.6M.
BioCryst Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1876 holding.
Susquehanna International Group first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
Susquehanna International Group's BioCryst Pharmaceuticals position peaked at $27.6M in Q4 2021.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.